Blog

Shedding New Light on Kinase Biochemistry through Physical Simulation and Machine Learning

Brenda Rubenstein/chemistry.brown.edu

Dec 15, 2024, 08:51

Shedding New Light on Kinase Biochemistry through Physical Simulation and Machine Learning

Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center, shared a post on LinkedIn:

“Outstanding presentation by Dr. Brenda Rubenstein at the Cancer Biology Program meeting at Legorreta Cancer Center, Brown U Cancer, The Warren Alpert Medical School of Brown University, Brown University, Robert W. Sobol Junior, Patrycja Dubielecka, Jeremy Warner and John Reagan.

She discussed machine learning approaches and use of dynamic simulations to understand cancer-drug target interactions and resistance mechanisms using Abl kinase as a model.”

Kinase Biochemistry

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.

More posts featuring Wafik S. El-Deiry.

Abl kinase Brenda Rubenstein Brown U Cancer Brown University cancer cancer-drug target drug target interactions Jeremy Warner John Reagan Legorreta Cancer Center OncoDaily Oncology Patrycja Dubielecka Robert W. Sobol The Warren Alpert Medical School Wafik S. El-Deiry

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage